Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024
Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL that offers patients full-range vision. Alongside this, Johnson & Johnson will present new data demonstrating successful surgical outcomes and high patient satisfaction from their cataract and refractive surgery portfolio. The company's retina research team will also showcase findings that emphasize the urgent need for approved therapies targeting inherited retinal diseases (IRDs).
The Tecnis Odyssey IOL is designed using proprietary technology aimed at providing superior image quality, even in challenging lighting conditions, while minimizing visual disturbances during nighttime vision. This new intraocular lens delivers an unparalleled range of vision with several key benefits:
- Enhanced tolerance to refractive errors
- Optimized dysphotopsia profile
- Unmatched range of vision
- Best-in-class contrast
In addition to unveiling the Tecnis Odyssey IOL, Johnson & Johnson said it will also feature its Catalys Precision Laser System, emphasizing its top industry position for laser cataract surgery (LCS) utilization, At AAO 2024, the company will demonstrate the latest version of the system’s software, cOS 7.1, which integrates with both biometers and topographers to provide better astigmatism management. This upgrade is expected to be available in the US in 2025.
Several investigator-initiated studies will be presented, underscoring positive results across Johnson & Johnson's ophthalmic solutions:
Induced Astigmatism Tolerance of an EDOF IOL with Violet-Light Filter
This study, led by Dr. Karolinne Rocha, evaluates how well patients tolerate induced astigmatism and examines refractive outcomes for eyes implanted with the Tecnis Symfony Optiblue IOL, which features a violet-light filter.Wavefront-Guided vs. Topography-Guided LASIK: A 12-Month Comparison
Dr. Edward Manche will present a prospective, randomized study comparing outcomes between wavefront-guided and topography-guided LASIK surgeries using the iDesign Refractive Studio, with promising results for treating myopia and astigmatism.
Johnson & Johnson’s Innovative Medicine group will share findings about the impact of IRDs on patients' quality of life. One key presentation, led by Dr. Byron Lam, will focus on:
- Real-World Comparison of Overall Survival among Patients with and without Inherited Retinal Diseases
This study highlights that IRDs, which affect over 2 million people worldwide, are the leading cause of blindness among working-age individuals. The findings show a significant reduction in quality of life and survival rate for patients with visual impairment from IRDs, underscoring the need for further advancements in therapy development.
Johnson & Johnson will be exhibiting at booth #4426 at AAO 2024, where visitors can explore their latest innovations and research in eye care.